SML2482

Sigma-Aldrich

Ticagrelor

≥98% (HPLC)

Synonym(s):
Ticagrelor, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5­(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Empirical Formula (Hill Notation):
C23H28F2N6O4S
CAS Number:
Molecular Weight:
522.57
MDL number:

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -55 to -65°, c = 0.2 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

CCCSC1=NC(N[C@@]2([H])[C@@](C3=CC=C(F)C(F)=C3)([H])C2)=C4C(N([C@@]5([H])[C@H](O)[C@H](O)[C@@H](OCCO)C5)N=N4)=N1

InChI

1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

InChI key

OEKWJQXRCDYSHL-FNOIDJSQSA-N

Gene Information

human ... P2RY12(64805)

General description

Ticagrelor (AZD6140) is a cyclopentyl-triazolopyrimidine.

Biochem/physiol Actions

Ticagrelor is an antithrombotic antiplatelet drug that acts by direct and reversible competitive inhibition of the adensoine purinoceptor P2Y12 receptor. It has clinical benefits in people affected with acute coronary syndrome. It might also play a beneficial role on endothelial function. Ticagrelor can prevent the uptake of adenosine by human erythrocytes and can promote the liberation of adenosine triphosphate (ATP) from human erythrocytes.

storage_class_code

11 - Combustible Solids

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

null
Michał J Kubisa et al.
Therapeutics and clinical risk management, 14, 129-140 (2018-02-06)
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor...
José C Nicolau et al.
Expert opinion on pharmacotherapy, 19(9), 1013-1019 (2018-06-13)
Cardiovascular disease (CVD) is the main cause of death in the world. Coronary artery disease (CAD) is the most common form of CVD presentation, but the prevalence of peripheral artery disease (PAD) is increasing. Patients with polyvascular disease comprise a...
Riyaad Aungraheeta et al.
Blood, 128(23), 2717-2728 (2016-10-04)
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought to further characterize its molecular mechanism of action. Initial studies showed that ticagrelor promoted...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service